Cargando…
Eliminating Visual Acuity and Dilated Fundus Examinations Improves Cost Efficiency of Performing Optical Coherence Tomogrpahy–Guided Intravitreal Injections
PURPOSE: The clinic efficiency and cost savings achieved by eliminating formal visual acuity (VA) and dilated fundus examinations (DFEs) were assessed for established patients receiving optical coherence tomography (OCT)–guided intravitreal injections. DESIGN: Comparative cost analysis. METHODS: Two...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329678/ https://www.ncbi.nlm.nih.gov/pubmed/32621894 http://dx.doi.org/10.1016/j.ajo.2020.06.028 |
_version_ | 1783552947108446208 |
---|---|
author | Trivizki, Omer Karp, Michael R. Chawla, Anuj Yamanuha, Justin Gregori, Giovanni Rosenfeld, Philip J. |
author_facet | Trivizki, Omer Karp, Michael R. Chawla, Anuj Yamanuha, Justin Gregori, Giovanni Rosenfeld, Philip J. |
author_sort | Trivizki, Omer |
collection | PubMed |
description | PURPOSE: The clinic efficiency and cost savings achieved by eliminating formal visual acuity (VA) and dilated fundus examinations (DFEs) were assessed for established patients receiving optical coherence tomography (OCT)–guided intravitreal injections. DESIGN: Comparative cost analysis. METHODS: Two different treatment models were evaluated. The first model included patients undergoing routine VA assessment, DFEs, OCT imaging, and intravitreal injections. The second model eliminated the routine VA assessment and DFE while using OCT imaging through an undilated pupil followed by the intravitreal injection. The 2 models incorporated both bevacizumab and aflibercept. The number of patients per clinic day, the cost per visit, and the daily revenues were compared between the 2 models. RESULTS: Optimized schedules with and without VA assessments and DFEs allowed for 48 and 96 patients to be injected per day, respectively. Excluding drug costs, the cost per encounter for the visits with and without a DFE were $39.33 and $22.63, respectively. Including the drug costs, the costs per encounter for the visits with and without a DFE were $85.55 and $68.85 for bevacizumab and $1787.58 and $17770.88 for aflibercept, respectively. Once the reimbursements for each visit type were included, the clinics that eliminated the VA and DFEs were more cost efficient. CONCLUSION: Eliminating both VA assessments and DFEs for patients undergoing OCT-guided retreatment with intravitreal injections resulted in decreased exposure times between patients and clinic staff, decreased cost per encounter, and increased patient volumes per clinic day, resulting in improved clinic efficiency and safety while seeing more patients in a clinic day. |
format | Online Article Text |
id | pubmed-7329678 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73296782020-07-02 Eliminating Visual Acuity and Dilated Fundus Examinations Improves Cost Efficiency of Performing Optical Coherence Tomogrpahy–Guided Intravitreal Injections Trivizki, Omer Karp, Michael R. Chawla, Anuj Yamanuha, Justin Gregori, Giovanni Rosenfeld, Philip J. Am J Ophthalmol Original Article PURPOSE: The clinic efficiency and cost savings achieved by eliminating formal visual acuity (VA) and dilated fundus examinations (DFEs) were assessed for established patients receiving optical coherence tomography (OCT)–guided intravitreal injections. DESIGN: Comparative cost analysis. METHODS: Two different treatment models were evaluated. The first model included patients undergoing routine VA assessment, DFEs, OCT imaging, and intravitreal injections. The second model eliminated the routine VA assessment and DFE while using OCT imaging through an undilated pupil followed by the intravitreal injection. The 2 models incorporated both bevacizumab and aflibercept. The number of patients per clinic day, the cost per visit, and the daily revenues were compared between the 2 models. RESULTS: Optimized schedules with and without VA assessments and DFEs allowed for 48 and 96 patients to be injected per day, respectively. Excluding drug costs, the cost per encounter for the visits with and without a DFE were $39.33 and $22.63, respectively. Including the drug costs, the costs per encounter for the visits with and without a DFE were $85.55 and $68.85 for bevacizumab and $1787.58 and $17770.88 for aflibercept, respectively. Once the reimbursements for each visit type were included, the clinics that eliminated the VA and DFEs were more cost efficient. CONCLUSION: Eliminating both VA assessments and DFEs for patients undergoing OCT-guided retreatment with intravitreal injections resulted in decreased exposure times between patients and clinic staff, decreased cost per encounter, and increased patient volumes per clinic day, resulting in improved clinic efficiency and safety while seeing more patients in a clinic day. Elsevier Inc. 2020-11 2020-07-02 /pmc/articles/PMC7329678/ /pubmed/32621894 http://dx.doi.org/10.1016/j.ajo.2020.06.028 Text en © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Trivizki, Omer Karp, Michael R. Chawla, Anuj Yamanuha, Justin Gregori, Giovanni Rosenfeld, Philip J. Eliminating Visual Acuity and Dilated Fundus Examinations Improves Cost Efficiency of Performing Optical Coherence Tomogrpahy–Guided Intravitreal Injections |
title | Eliminating Visual Acuity and Dilated Fundus Examinations Improves Cost Efficiency of Performing Optical Coherence Tomogrpahy–Guided Intravitreal Injections |
title_full | Eliminating Visual Acuity and Dilated Fundus Examinations Improves Cost Efficiency of Performing Optical Coherence Tomogrpahy–Guided Intravitreal Injections |
title_fullStr | Eliminating Visual Acuity and Dilated Fundus Examinations Improves Cost Efficiency of Performing Optical Coherence Tomogrpahy–Guided Intravitreal Injections |
title_full_unstemmed | Eliminating Visual Acuity and Dilated Fundus Examinations Improves Cost Efficiency of Performing Optical Coherence Tomogrpahy–Guided Intravitreal Injections |
title_short | Eliminating Visual Acuity and Dilated Fundus Examinations Improves Cost Efficiency of Performing Optical Coherence Tomogrpahy–Guided Intravitreal Injections |
title_sort | eliminating visual acuity and dilated fundus examinations improves cost efficiency of performing optical coherence tomogrpahy–guided intravitreal injections |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329678/ https://www.ncbi.nlm.nih.gov/pubmed/32621894 http://dx.doi.org/10.1016/j.ajo.2020.06.028 |
work_keys_str_mv | AT trivizkiomer eliminatingvisualacuityanddilatedfundusexaminationsimprovescostefficiencyofperformingopticalcoherencetomogrpahyguidedintravitrealinjections AT karpmichaelr eliminatingvisualacuityanddilatedfundusexaminationsimprovescostefficiencyofperformingopticalcoherencetomogrpahyguidedintravitrealinjections AT chawlaanuj eliminatingvisualacuityanddilatedfundusexaminationsimprovescostefficiencyofperformingopticalcoherencetomogrpahyguidedintravitrealinjections AT yamanuhajustin eliminatingvisualacuityanddilatedfundusexaminationsimprovescostefficiencyofperformingopticalcoherencetomogrpahyguidedintravitrealinjections AT gregorigiovanni eliminatingvisualacuityanddilatedfundusexaminationsimprovescostefficiencyofperformingopticalcoherencetomogrpahyguidedintravitrealinjections AT rosenfeldphilipj eliminatingvisualacuityanddilatedfundusexaminationsimprovescostefficiencyofperformingopticalcoherencetomogrpahyguidedintravitrealinjections |